Common Contracts

Contract

June 17th, 2021

• Filed
  June 17th, 2021

Clinical Trial Agreement Protocol # MOR208C310Trial Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R- CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) This Clinical Trial Agreement (“Agreement”) is entered into by and among the following parties: MorphoSys AG, a German company with a principal place of business at Semmelweisstrasse 7, 82152 Planegg, Germany (“Sponsor”) and National Oncologic Institute, with a place of business at Klenová 1, 833 10 Bratislava, Slovak republic, ID: 00165 336, VAT ID: SK2020830108, Based on the Act No 27.11.1965 No Z-8025/1965-VI/B-2 as lateramended , represented by ' ', general director and, medical director (“Institution”); and Assoc. Prof. Ľuboš Drgoňa, MD., with a place of business at , Slovakrepublic (“PI”), and shall become effective as of t